Compare · ABT vs IPEX
ABT vs IPEX
Side-by-side comparison of Abbott Laboratories (ABT) and Inflection Point Acquisition Corp. V (IPEX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and IPEX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT carries a market cap of $188.12B.
- Over the past year, ABT is down 18.1% and IPEX is up 5.1% - IPEX leads by 23.2 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- ABT has more recent analyst coverage (25 ratings vs 0 for IPEX).
- Company
- Abbott Laboratories
- Inflection Point Acquisition Corp. V
- Price
- $105.28-2.59%
- $10.55+0.38%
- Market cap
- $188.12B
- -
- 1M return
- +16.10%
- +0.38%
- 1Y return
- -18.11%
- +5.08%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 4
- 4
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
Latest IPEX
- SEC Form DEF 14A filed by Inflection Point Acquisition Corp. V
- SEC Form 425 filed by Inflection Point Acquisition Corp. V
- Inflection Point Acquisition Corp. V filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form PRE 14A filed by Inflection Point Acquisition Corp. V
- GOWell Technology Limited and Inflection Point Acquisition Corp. V Announce Public Filing of Amendment No. 1 to the Registration Statement on Form F-4 in Connection with Proposed Business Combination
- Amendment: SEC Form SCHEDULE 13G/A filed by Inflection Point Acquisition Corp. V
- SEC Form 425 filed by Inflection Point Acquisition Corp. V
- Inflection Point Acquisition Corp. V filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 425 filed by Inflection Point Acquisition Corp. V
- Inflection Point Acquisition Corp. V filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits